Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses (2011 - 2018)

Vanda Pharmaceuticals (VNDA) has 8 years of Other Accumulated Expenses data on file, last reported at $4.4 million in Q1 2018.

• For the quarter ending Q1 2018, Other Accumulated Expenses rose 134.23% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2018 stood at $4.4 million (up 134.23% YoY), and the FY2017 full-year result was $4.4 million, down 3.53% from the prior year.
• Other Accumulated Expenses declined to $4.4 million in Q1 2018, from $4.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.4 million in Q3 2016 to a low of $614000.0 in Q1 2014.
• A 5-year average of $2.9 million and a median of $2.0 million in 2014 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 4555.56% in 2014 and slumped 69.76% in 2017, its largest moves.
• Tracing VNDA's Other Accumulated Expenses over 5 years: stood at $2.0 million in 2014, then soared by 163.76% to $5.3 million in 2015, then slipped by 14.51% to $4.6 million in 2016, then fell by 3.53% to $4.4 million in 2017, then declined by 0.96% to $4.4 million in 2018.
• Business Quant data shows VNDA's Other Accumulated Expenses at $4.4 million in Q1 2018, $4.4 million in Q4 2017, and $1.9 million in Q3 2017.